Cetilistat, a new lipase inhibitor for the treatment of obesity

Current Opinion in Investigational Drugs

Volumn 9, Issue 4, 2008, Pages 414-421

  Padwal, R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CETILISTAT; METFORMIN; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DEFECATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FLATULENCE; HEADACHE; HUMAN; LOOSE FECES; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OILY STOOL; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

ANIMALS; ANTI-OBESITY AGENTS; BENZOXAZINES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; LIPASE; MOLECULAR STRUCTURE; OBESITY; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 41949142561     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. 217798 Alizyme seeks to raise $15M in placement on alternative investment market. BIOWORLD INT 1996 1 25 1-7
2. 232730 A placing by Beeson Gregory (pharmaceutical analysis update). Alizyme Ltd COMPANY PROSPECTUS 1996 October 15
3. 323072 Drug candidate identified for obesity treatment. Alizyme plc PRESS RELEASE 1999 April 22
4. 373713 Alizyme's ATL-962 completes phase Ia trial. Alizyme plc PRESS RELEASE 2000 July 07
5. 385867 Alizyme granted approval to commence phase Ib clinical trial for obesity drug ATL-962. Alizyme plc PRESS RELEASE 2000 October 16
6. 395528 Alizyme announces positive phase Ib trial results for ATL-962. Alizyme plc PRESS RELEASE 2001 January 08
7. 459096 Drug development pipeline - ATL-962. Alizyme plc COMPANY COMMUNICATION 2002 July 24
8. 462603 Alizyme discloses phase Ib data for obesity drug. Alizyme plc PRESS RELEASE 2002 August 27
9. 493245 Increased faecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962. Dunk C, Enunwa M, de la Motte S, Palmer RMJ INT J OBESITY 2002 26 Suppl 1 S135
10. 500601 Alizyme grants rights to Takeda to license and develop obesity drug for Japan worth up to US $42 million. Alizyme plc PRESS RELEASE 2003 August 08
11. 520685 Takeda exercises rights to licence to develop Alizyme's obesity drug for Japan. Alizyme plc PRESS RELEASE 2004 January 30
12. 596894 Alizyme halves loss in 2004 and plans $58 million placement. Alizyme plc PRESS RELEASE 2005 April 21
13. 1-antagonists and lipase inhibitors. Jochen A, Gregory PC, Krause G WORLD PATENT 2005 May 06
14. 615753 Alizyme plc (LSE:AZM) announces that recruitment for the phase I pharmacokinetic/pharmacodynamic clinical trial of cetilistat in obese volunteers in the USA has been successfully completed. Alizyme plc PRESS RELEASE 2005 August 02
15. 618820 The efficacy and safety of sibutramine for weight loss. A systematic review. Arterburn DE, Crane PK, Veenstra DL ARCH INTERN MED 2004 164 9 994-1003
16. 640063 Alizyme announces preliminary results from its successful phase IIb clinical trial of cetilistat in obese diabetics. Alizyme plc PRESS RELEASE 2005 December 12
17. 646241 Takeda starts phase II clinical studies of ATL-962, a treatment for obesity and related diseases in Japan. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2006 January 20
18. 646248 Alizyme to receive US$2 million milestone from Takeda on entry of cetilistat into phase II clinical development in Japan. Alizyme plc PRESS RELEASE 2006 January 20
19. 672471 Orexigen Therapeutics to present first clinical results for Contrave to treat obesity. Orexigen Therapeutics Inc PRESS RELEASE 2006 June 07
20. 672868 Safety and tolerability of cetilistat (ATL-962), a novel lipase inhibitor, in obese, otherwise-healthy, North-American, caucasian subjects in a repeat dose pharmacokinetic study. Galitz LA, Bryson A, Hallam R DIABETES 2006 55 6 Suppl 1 1705 P
21. 672871 A randomised, placebo-controlled, trial of cetilistat (ATL-962), a novel lipase inhibitor, and orlistat (Xenical) for the management of obese type 2 diabetic patients. Kopelman PG, De Groot GGH, Rissanen AM, Rossner S, Toubro S, Bryson A, Hallam R DIABETES 2006 55 6 Suppl 1 1711 P
22. 675042 Acomplia (rimonabant) receives marketing authorisation in the European Union. sanofi-aventis PRESS RELEASE 2006 June 21
23. 682102 FDA clears Alizyme's obesity drug, cetilistat, for phase III trials Alizyme plc PRESS RELEASE 2006 August 02
24. 740697 Efficacy and tolerability of ATL-962, a lipase inhibitor, in obese patients. Peter K, Andrew B, Richard P INT J OBESITY 2004 28 Suppl 1 S28
25. 764216 Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Padwal RS, Majumdar SR LANCET 2007 369 9555 71-77
26. 765430 sanofi-aventis 2006: In a difficult environment, another year of growth in adjusted EPS excluding selected items. sanofiaventis PRESS RELEASE 2007 February 13
27. 791806 Cetilistat (ATL-962), a novel lipase inhibitor: A 12-week randomized, placebo-controlled study of weight reduction in obese patients. Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P INT J OBESITY 2007 31 3 494-499
28. 804452 FDA advisory committee did not recommend approval of rimonabant (Zimulti) for use in obese and overweight patients with associated risk factors. sanofi-aventis PRESS RELEASE 2007 June 13
29. 818983 Interim report 2007. Alizyme plc 2ND QUARTER REPORT 2007 July 19
30. 854607 Takeda: Product pipeline. Takeda Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2007 November 05
31. 859886 Merck reviews progress on strategic plan at 2007 Annual Business Briefing. Merck & Co Inc PRESS RELEASE 2007 December 11
32. 859950 Alizyme: Products overview. Alizyme plc COMPANY WORLD WIDE WEB SITE 2007 December 11
33. 860408 VIVUS initiates third Qnexa phase 3 trial in obese patients. VIVUS Inc PRESS RELEASE 2007 December 12
34. 860755 Arena to start two further phase III obesity trials of lorcaserin. Arena Pharmaceuticals Inc PRESS RELEASE 2007 December 13
35. 865890 Cardiovascular responses to weight management and sibutramine in high-risk subjects: An analysis from the SCOUT trial. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P, SCOUT Investigators EUR HEART J 2007 28 23 2915-2923
36. 866900 Obesity. Haslam DW, James WP LANCET 2005 366 9492 1197-1209
37. 867204 Sibutramine: A review of its contribution to the management of obesity. McNeely W, Goa KL DRUGS 1998 56 6 1093-1124
38. 867319 Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Padwal R, Li SK, Lau DCW INT J OBES RELAT METAB DISORD 2003 27 12 1437-1446
39. 867346 Rimonabant for overweight or obesity. Curioni C, Andre C COCHRANE DATABASE SYST REV 2006 4 CD006162
40. 867347 Orlistat for the management of overweight individuals and obesity: A review of potential for the 60-mg, over-the-counter dosage. Anderson W EXPERT OPIN PHARMACOTHER 2007 8 11 1733-1742
41. 867364 Obese patients' perceptions of treatment outcomes and the factors that influence them. Foster GD, Wadden TA, Phelan S, Sarwer DB, Sanderson RS ARCH INTERN MED 2001 161 17 2133-2139
42. 867365 Long-term persistence with orlistat and sibutramine in a population-based cohort. Padwal RS, Kezouh A, Levine M, Etminan M INT J OBESITY 2007 31 10 1567-1570
43. 867366 WO-00040569: 2-Oxy-4H-3,1-benzoxazin-4-ones for treatment of obesity. Hodson HF, Downham R, Mitchell TJ, Carr BJ, Dunk CR, Palmer RM WORLD PATENT 2000 July 13
44. 867367 A systematic review of the clinical effectiveness of orlistat used for the management of obesity. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G OBES REV 2004 5 1 51-68
45. 867372 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM N ENGL J MED 2002 346 6 393-403
46. 867373 Barriers to the treatment of obesity. Bray GA ANN INTERN MED 1991 115 2 152-153
47. 867374 Pharmacotherapy for obesity. Ioannides-Demos LL, Proietto J, McNeil JJ DRUGS 2006 65 10 1391-1418.
48. 867375 Phenylpropanolamine and the risk of hemorrhagic stroke. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI N ENGL J MED 2000 343 25 1826-1832
49. 867377 Appetite-suppressant drugs and the risk of primary pulmonary hypertension. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G et al N ENGL J MED 1996 335 9 609-616
50. 867378 Valvular heart disease associated with fenfluraminephentermine. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV N ENGL J MED 1997 337 9 581-588
51. 867643 The Surgeon General's call to action to prevent and decrease overweight and obesity. Rockville MD US DEPARTMENT OF HEALTH AND HUMAN SERVICES, PUBLIC HEALTH SERVICE, OFFICE OF THE SURGEON GENERAL 2001
52. 867668 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. National Institutes of Health. OBES RES 1998 6 Suppl 2 51S-209S
53. 867681 Commercial weight loss products and programs: What consumers stand to gain and lose. A public conference on the information consumers need to evaluate weight loss products and programs. Cleland R, Graybill DC, Hubbard V, Khan LK, Stern JS, Wadden TA, Weinsier R, Yanovski S, Gross WC, Daynard M CRIT REV FOOD SCI NUTR 2001 41 1 45-70
54. 867707 Diet pill alli sales in June 'exceeding expectations' - GlaxoSmithKline. AlliReport WEBSITE 2007 30 June
55. 867709 Orlistat-associated adverse effects and drug interactions: A critical review. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS DRUG SAF 2008 31 1 53-65
56. 867712 US-06624161: 2-Oxy-benzoxazinone derivatives for the treatment of obesity. Hodson HF, Downham R, Mitchell TJ, Carr BJ, Dunk CR, Palmer RMJ US PATENT 2003 February 06
57. 867714 Xenical (orlistat): Patient information. Roche Holding AG DRUG DATASHEET WEBSITE 2004 October 30
58. 867718 Drugstore.com - the uncommon drugstore. WEB SITE 2007 October 25
59. 867719 Aminorex to Fen/Phen: An epidemic foretold. Fishman AP CIRCULATION 1999 99 1 151-161
60. 867724 Obesity drug sibutramine (Meridia): Hypertension and cardiac arrhythmias. Wooltorton E CMAJ 2002 166 10 1307-1308
61. 867726 NCT00263042: Comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes (CRESCENDO). sanofi-aventis CLINICALTRIALS.GOV 2005 December 06
62. 867729 Digestive lipases: From three-dimensional structure to physiology. Miled N, Canaan S, Dupuis L, Roussel A, Rivière M, Carrière F, de Caro A, Cambillau C, Verger R BIOCHIMIE 2000 82 11 973-986
63. 875015 Obesity: New products on the horizon. IMS Health WEB SITE 2006 May 31
64. 875016 National trends in antiobesity medication use. Stafford RS, Radley DC ARCH INTERN MED 2003 163 9 1046-1050
65. 875018 National trends in the use and costs of anti-obesity medications in England 1998-2005. Srishanmuganathan J, Patel H, Car J, Majeed A J PUB HEALTH 2007 29 2 199-202
66. 875019 Press coverage and sales of Xenical in Sweden, 1998-2000. Brouneus F, Dahlin A, Beermann B EUR J CLIN PHARMACOL 2005 61 4 285-289
67. 875028 Orlistat in the long-term treatment of obesity in primary care settings. Hauptman J, Lucas C, Boldrin M, Collins H, Segal KR ARCH FAM MED 2000 9 2 160-167
68. 875029 Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G OBES RES 2000 8 1 49-61
69. 877642 FDA announces withdrawal of fenfluramine and dexfenfluramine. US FDA CDER WEEKLY BULLETIN 1997 September 15
70. 877648 Phenylpropanolamine (PPA) information page. US FDA CDER WEEKLY BULLETIN 2005 December 23
71. 877671 FDA announces rule prohibiting sale of dietary supplements containing ephedrine alkaloids effective April 12. FDA DRUG BULL 2004 April 12